On this page
RFXANK
regulatory factor X associated ankyrin containing protein
The RFXANK gene provides instructions for a protein crucial to the immune system, particularly in regulating major histocompatibility complex (MHC) class II genes. The RFXANK gene is fundamental for proper immune function, directing the creation of a protein that controls the activity of MHC class II genes.
RFXANK is located on the short (p) arm of chromosome 19, at band 19p13.11. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 19 in the library →Available at Jeen Health
Clinical tests that include this
Overview
The RFXANK gene, or regulatory factor X associated ankyrin containing protein, is vital for the human immune system. It produces a protein that is part of the regulatory factor X (RFX) complex, which helps control the activity of major histocompatibility complex (MHC) class II genes.
MHC class II proteins are critical components of immune cells, enabling the body to identify and neutralise foreign substances such as bacteria and viruses. Dysfunction of the RFXANK gene can impair this essential immune response.
What the gene does
The RFXANK protein is an integral subunit of the regulatory factor X (RFX) complex. This complex is responsible for binding to specific DNA regions, thereby regulating the transcription of major histocompatibility complex (MHC) class II genes. Transcription is the initial step in producing proteins, and RFXANK ensures the precise production of MHC class II proteins.
MHC class II proteins are displayed on the surface of various immune cells, including lymphocytes. Their primary role is to present fragments of foreign proteins, known as peptides, to other immune cells. This presentation mechanism allows the immune system to recognise threats and initiate a targeted response against pathogens. While the RFX complex also influences MHC class I gene activity, its primary regulatory role lies with MHC class II genes.
Video: Genetics 101
Chromosome location
The RFXANK gene is situated on chromosome 19, specifically at position 19p13.11. This genomic location defines its place within the human genome.
Protein structure
The RFXANK protein consists of 260 amino acids. Its structure includes a disordered region spanning amino acids 1-79. Following this, the protein contains five ankyrin repeat domains: ANK 1 (amino acids 89-118), ANK 2 (amino acids 123-152), ANK 3 (amino acids 156-185), ANK 4 (amino acids 189-218), and ANK 5 (amino acids 222-251). These ankyrin repeats are typically involved in protein-protein interactions.
Key variants
Genetic variations within the RFXANK gene can affect its ability to produce a functional protein, leading to impaired immune responses. Over 40 different mutations have been identified in individuals with associated health conditions. These variants can impact the gene's regulatory function over MHC class II genes, disrupting the body's defence mechanisms.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.232C>T | p.Arg78Ter | Pathogenic/Likely pathogenic | ★★☆☆ | MHC class II deficiency |
c.271+1G>C | - | Pathogenic/Likely pathogenic | ★★☆☆ | MHC class II deficiency |
c.338-25_338del | - | Pathogenic | ★★☆☆ | MHC class II deficiency 1 |
c.362A>T | p.Asp121Val | Pathogenic/Likely pathogenic | ★★☆☆ | MHC class II deficiency 1 |
c.437G>A | p.Trp146Ter | Pathogenic/Likely pathogenic | ★★☆☆ | MHC class II deficiency |
c.438+1G>T | - | Pathogenic/Likely pathogenic | ★★☆☆ | Inborn genetic diseases |
c.454_455del | p.Ile152fs | Pathogenic/Likely pathogenic | ★★☆☆ | MHC class II deficiency 2 |
c.481del | p.Leu161fs | Pathogenic/Likely pathogenic | ★★☆☆ | MHC class II deficiency |
c.558T>A | p.Tyr186Ter | Pathogenic/Likely pathogenic | ★★☆☆ | RFXANK-related disorder |
c.634C>T | p.Arg212Ter | Pathogenic | ★★☆☆ | MHC class II deficiency |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Mutations in the RFXANK gene are the most frequent genetic cause of an immune system disorder known as bare lymphocyte syndrome type II (BLS II). This condition is a type of combined immunodeficiency, where affected individuals exhibit severely compromised immune protection against various foreign invaders. Consequently, individuals with BLS II are highly susceptible to recurrent and severe infections.
No condition pages are linked to this gene yet. This does not mean it has no associated conditions.
UK clinical status
The RFXANK gene is included in certain NHS Genomic Medicine Service panels. It is listed with a 'green' status on the COVID-19 research panel and the Primary immunodeficiency or monogenic inflammatory bowel disease panel (R15), indicating its relevance in these clinical contexts within the UK.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Frequently asked questions
What is the primary role of the RFXANK gene?
The RFXANK gene provides instructions for a protein that helps regulate the activity of major histocompatibility complex (MHC) class II genes, which are essential for immune system function.
Which condition is most commonly associated with RFXANK gene mutations?
Mutations in the RFXANK gene are the most common genetic cause of bare lymphocyte syndrome type II (BLS II), a severe immune deficiency disorder.
How does the RFXANK protein contribute to immunity?
The RFXANK protein is part of a complex that ensures the proper production of MHC class II proteins. These proteins are critical for immune cells to recognise and respond to foreign invaders.
References
- Garvie CW, Boss JM. Assembly of the RFX complex on the MHCII promoter: role of RFXAP and RFXB in relieving autoinhibition of RFX5. Biochimica et biophysica acta. 2008. PMID: 18723135
- Burd AL, Ingraham RH, Goldrick SE. Assembly of major histocompatibility complex (MHC) class II transcription factors: association and promoter recognition of RFX proteins. Biochemistry. 2004. PMID: 15461447
- Masternak K, Barras E, Zufferey M. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients. Nature genetics. 1998. PMID: 9806546
- Gobin SJ, Peijnenburg A, van Eggermond M. The RFX complex is crucial for the constitutive and CIITA-mediated transactivation of MHC class I and beta2-microglobulin genes. Immunity. 1998. PMID: 9806639